Printer Friendly

Mutation scanning the GJB1 gene with high-resolution melting analysis: implications for mutation scanning of genes for Charcot-Marie-Tooth disease.

Charcot-Marie-Tooth (CMT) neuropathy is the most common group of hereditary disorders presenting to genetic clinics and affects ~1 in 2500 individuals (1). The CMT syndrome includes many hereditary disorders of peripheral nerves and affects both motor and sensory neurons. Patients suffering from CMT show progressive distal wasting and weakness, pes cavus or foot drop, and loss of deep tendon reflexes. X-linked CMT (CMTX) is the 2nd most common form of demyelinating CMT after Charcot-Marie-Tooth disease type 1A and accounts for 10%-15% of all CMT cases (2). CMTX1 (MIM 302800) is an X-linked dominant trait caused by mutations in the GJB1 [gap junction protein, beta 1, 32kDa (connexin 32, Charcot-Marie-Tooth neuropathy, X-linked)] gene (3). Over 280 mutations have been reported in this gene according to the Inherited Peripheral Neuropathies Mutation Database (www.molgen.ua.ac.be/CMTMutations).

Our laboratory currently uses sequencing to identify gene mutations in the GJB1 gene. High-resolution melting (HRM) curve analysis is a powerful tool for scanning entire amplicons and detecting sequence variations, made possible through the discovery of the saturating double-stranded (ds) DNA dye, LC Green Plus (4), and by advances in instrumentation that enable acquisition of high-resolution fluorescent data (5). LC Green Plus (Idaho Technology) can be used at concentrations that do not inhibit PCR amplification but efficiently saturate PCR products. HRM analysis of PCR products amplified in the presence of LC Green Plus can detect heterozygous and most homozygous sequence variations by the difference in shape and position of the melting curve when compared with a wild-type melt profile (4, 6). The method would therefore be amenable to screening an X-linked dominant disorder with heterozygous females and hemizygous male patients.

Informed consent for DNA studies was obtained from all patients according to protocols approved by the Concord Hospital and the University of Antwerp Ethics Review Committees. To validate the HRM method, we selected 18 known patient samples that were positive for GJB1 mutations (10 males and 8 females) and 4 control individuals (3 females and 1 male). In addition, 10 deidentified DNA samples (6 males, 4 females) with and without GJB1 mutations were selected for blind analysis from the Molecular Genetics Department, University of Antwerp, Belgium. The control and patient samples used in both the validation and blind study were previously confirmed by sequence analysis with primers described by Bergoffen et al. (3). The GenBank sequence NM_ 000166 was used as the reference sequence for the cDNA. Nucleotide numbering of the A in the ATG translation initiation site was designated +1. There is 1 reported single-nucleotide polymorphism (SNP; rs11551260) in the coding sequence of the GJB1 gene; however, none of the individuals used in this study contained the SNP (c.287 C>G).

Primers to amplify 4 overlapping amplicons were designed with the Oligo Program Version 6 (Molecular Biology Insights) to provide comprehensive coverage of the GJB1 single-exon 852-bp open reading frame. Primer information, fragment size, fragment coverage, and pathogenic codons are shown in Table 1. Fragments 1, 2, and 4 provided adequate coverage for gene scanning, and fragment 3 was designed to test for mutations close to the primer. To facilitate heteroduplex formation, samples from hemizygous males were mixed with samples of male wild-type DNA (1:1 w/w) before PCR amplification. Amplifications were performed in 10-[micro]L reactions containing 50 ng DNA, 200 [micro]mol/L dNTP, 1 U Bio-X-Act Taq Polymerase (Bioline), 3 mmol/L Mg[Cl.sub.2], 2X PCR Enhancer (Invitrogen) 0.6X LC Green Plus (Idaho Technology), and 0.25 [micro]mol/L primers. PCR was performed on either a 9700 thermocycler (Applied Biosystems) or Mastercycler (Eppendorf) with an initial denaturation of 95[degrees]C for 5 min, followed by 35-40 cycles of 95[degrees]C for 30 s, 55[degrees]C for 30 s, and 68[degrees]C for 40 s, with a final extension of 68[degrees]C for 5 min. We used LC Green Plus at 0.6X in our reactions and found no difference in the fluorescence detection sensitivity at this concentration compared with the 1X concentration. To facilitate heteroduplex formation, we subjected the samples to a 2-temperature hold profile (95[degrees]C for 5 s followed by 50[degrees]C for 5 min).

We performed melting acquisition on a 96-well LightScanner (Idaho Technology). The plate was heated from 80[degrees]C to 98[degrees]C at 0.1[degrees]C/s with a 300-ms frame interval, 15-ms exposure, and 100% LED power, giving ~14 points/[degrees]C (5, 7). Melting-curve analysis was performed by use of previously described methods (7) with LightScanner Software (version 1.0.1.524). Melting curves were normalized by selecting linear regions before and after the melting transition. These regions were defined for each curve, with an upper (100%)fluorescence and lower (0%) baseline being common for all curves. To eliminate slight temperature errors between samples, the normalized melting curves were temperature shifted by moving the curves along the X-axis to bring them through a common temperature that facilitates clustering into groups. To avoid false negatives, we performed this procedure at a temperature at which the entire mixture of duplexes had melted. Fluorescent difference curves were generated from normalized temperature-shifted data by selecting a control for comparison and subtracting the fluorescence of the control from all other melting curves. The fluorescence difference between all other curves and the comparison curve was then plotted against temperature.

A total of 18 known GJB1 mutations (mutations 1-18, Fig. 1A-1F.) were used to validate the HRM method. Mutation detection sensitivity was 100% for all the known mutations. The control (wild-type) sample melting curves grouped tightly for all fragments, and altered difference curves were easily distinguished for the 18 mutations. HRM analysis also demonstrated detection sensitivity for mutations close to the primer. The mutations located closest to either end of fragment 3 were present in patient 7 (located 3-bp in from the 5' end of the forward primer) and in patient 16 (located 2-bp from the 3' end of the reverse primer). In both instances, the mutations gave altered melting curves compared with the control group (Fig. 1C and 1D). The 2 deletion mutations in patients 5 and 7 clearly showed an altered fluorescence curve for the 1-bp (Fig. 1A) and the 18-bp deletion (Fig. 1B and 1C) compared with the wild-type profile. For the blind analysis, the same controls used in the validation experiments were amplified in addition to the 10 deidentified samples. Mutation detection sensitivity was 100%, with 5 of 5 mutations (mutations 19-23, Fig. 1G-1I) being identified. Altered melting curves were observed on fragments 1, 3, and 4 and samples negative for mutations grouped tightly with the known control melting profiles. The melting curves for mutation 23 (509T>A) confirmed localization of the base change to an overlapping region on fragments 3 and 4. Mutations 1 (Fig. 1A), 8, 10 (Fig. 1B and 1C), 18 (Fig. 1F), and 21 (Fig. 1G) are previously unreported novel mutations that further demonstrate the allelic heterogeneity of CMTX1.

We have demonstrated a rapid and sensitive method for mutation scanning the GJB1 gene by use of the ds DNA-binding dye LC Green Plus and a 96-well format dedicated melting and detection instrument (LightScanner). GJB1 provided an excellent gene model, enabling us to analyze many different mutations spanning the GJB1 gene. The HRM results for the 18 known mutations and the detection of the 5 mutations in the blind study were 100% concordant with the results obtained by sequencing. We recognize that HRM analysis will not replace sequencing for confirmation of altered fluorescence melt curves; however, in a gene scanning scenario, samples in the blind study producing a melt curve consistent with known normal controls would not be sequenced, a situation that demonstrates the potential of this technology to reduce sequencing burden. Although the GJB1 gene contained a reported SNP (rs11551260), retrospective sequence analysis of all individuals confirmed the absence of this neutral variant in our study, as evidenced by the tight grouping of control samples in fragment 1 of both the validation (Fig. 1A) and blind (Fig. 1I) study. Accounting for reported SNPs in an amplicon is important in HRM analysis, as is eliminating the amplification of neutral intronic DNA variants through primer design. These neutral variants will produce altered fluorescence difference curves and will require sequence analysis because the specificity of scanning methods is not 100%.

[FIGURE 1 OMITTED]

We have shown that HRM analysis requires simple PCR protocols to prepare samples for melting curve analysis, and that the method has the sensitivity required for the detection of deletion gene rearrangements. Other methods relying on heteroduplex formation to detect sequence variation [e.g., dHPLC and temperature gradient capillary electrophoresis (TGCE)] often fail to detect small homozygous insertions and deletions unless sequential analyses are performed and manual processing is undertaken (8). Our findings complement the report for detecting internal tandem duplications (ranging from 6 by to 102 bp) by this method (9).

Because HRM can scan an entire amplicon for sequence variation, this method is ideal for screening the complete open reading frame of a gene. Although the coding region of the GJB1 gene is only a single-exon gene, it allowed us to test and validate HRM as a gene-scanning method for an X-linked disorder, in which all heterozygous female and homozygous male mutations were detected. In contrast, many of the genes reported for CMT are large (>15 exons) e.g., DNM2 (dynamin 2) and MFN2 (mitofusin 2), and would be suited to this method of mutation scanning. We have estimated the cost of reagents to be $0.60 per sample per amplicon, which is one tenth of our current sequencing cost. HRM analysis of single exons of large multiexon genes is a simple, sensitive, and cost-efficient gene-scanning method that would clearly reduce the sequencing burden.

Previously published online at D01: 10.1373/clinchem.2006.080010

References

(1.) Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 1974;6:98-118.

(2.) lonasescu VV, Searby C, lonasescu R, Neuhaus IM, Werner R. Mutations of the noncoding region of the connexin32 gene in X-linked dominant Charcot-Marie-Tooth neuropathy. Neurology 1996;47:541-4.

(3.) Bergoffen J, Scherer SS, Wang S, Scott M0, Bone U, Paul DL et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993;262: 2039-42.

(4.) Withver CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 2003; 49:853-60.

(5.) Herrmann MG, Durtschi JD, Bromley LK, Wittwer CT, Voelkerding KV. Amplicon DNA melting analysis for mutation scanning and genotyping: cross-platform comparison of instruments and dyes. Clin Chem 2006;52:494-503.

(6.) Gundry CN, Vandersteen JG, Reed GH, Pryor RJ, Chen J, Wittwer CT. Amplicon melting analysis with labeled primers: a closed-tube method for differentiating homozygotes and heterozygotes. Clin Chem 2003;49:396-406.

(7.) Zhou L, Wang L, Palais R, Pryor R, Withver CT. High-resolution DNA melting analysis for simultaneous mutation scanning and genotyping in solution. Clin Chem 2005;51:1770-7.

(8.) Palais RA, Liew MA, Withver CT. Quantitative heteroduplex analysis for single nucleotide polymorphism genotyping. Anal Biochem 2005;346:167-75.

(9.) Vaughn CP, Elenitoba-Johnson KS. High-resolution melting analysis for detection of internal tandem duplications. J Mol Diagn 2004;6:211-6.

Marina L. Kennerson, [1,2] * Trent Warburton, [3] Eva Nelis, [4] Megan Brewer, [5] Patsie Polly, [5] Peter De Jonghe, [4] Vincent Timmerman, [6] and Garth A. Nicholson, [1,2]

[1] Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord NSW, Australia;

[2] Molecular Medicine Laboratory, Concord Hospital, Concord NSW, Australia;

[3] John Morris Scientific, Victoria, Australia;

[4] Neurogenetics Group and

[6] Peripheral Neuropathy Group, Department of Molecular Genetics, Flanders Interuniversity Institute for Biotechnology, Institute Born-Bunge, University of Antwerp, Antwerpen, Belgium;

[5] Department of Pathology, School of Medical Sciences, University of New South Wales, Kensington, NSW, Australia;

* address correspondence to this author at: Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, NSW, Australia 2139; fax 61-2-97679101, e-mail marinak@anzac.edu.au)
Table 1. Primers, amplicon size, open reading frame coverage, and
pathogenic codons.

Fragment Primers 5' to 3' Amplicon Coverage
 size, bp of ORF, (a) bp

1 AAG GTG TGA ATG AGG CAG 346 1-328
 CTC AAG CCG TAG CAT TTT C

2 CAC CAG CAA CAC ATA GAG 185 289-473
 GGG TAG AGC AGA TAA AAG

3 AAT GCT ACG GCT TGA GG 256 312-567
 GAC GGT TTT CTC GGT GGG

4 GGT GTT CCG GCT GTT GTT 458 417-852

 GCA GGT TGC CTG GTA TGT

Fragment Primers 5' to 3' Codon (mutation number) (b)

1 AAG GTG TGA ATG AGG CAG 18 (1) 22 (2) 28 (3)
 CTC AAG CCG TAG CAT TTT C 35 (4) 73 (5) 94 (6)
 26 (19) 49 (20) 82 (21)

2 CAC CAG CAA CAC ATA GAG 111-116 (7) 132 (8),
 GGG TAG AGC AGA TAA AAG 141 (9) 151 (10)

3 AAT GCT ACG GCT TGA GG 111-116 (7) 132 (8)
 GAC GGT TTT CTC GGT GGG 141 (9) 151 (10), 154 (11) 159
 (12), 164 (13) 181 (14), 182
 (15) 183 (16) 170 (23)

4 GGT GTT CCG GCT GTT GTT 141 (9) 151 (10) 154 (11) 159
 (12) 164 (13) 181 (14) 182
 (15) 183 (16)
 GCA GGT TGC CTG GTA TGT 205 (17) 226 (18)
 213 (22) 170 (23)

(a) Open reading frame.
(b) Pathogenic codons detected within each of the overlapping
amplicons are shown. The numbers in brackets refer to the patient
mutation numbers in Figure 1. The reported neutral variant
(rs11551260) on amplicon 1 can be present in codon 96.
COPYRIGHT 2007 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Technical Briefs
Author:Kennerson, Marina L.; Warburton, Trent; Nelis, Eva; Brewer, Megan; Polly, Patsie; De Jonghe, Peter;
Publication:Clinical Chemistry
Article Type:Clinical report
Date:Feb 1, 2007
Words:2248
Previous Article:Lateral flow immunoassay using europium (III) chelate microparticles and time-resolved fluorescence for eosinophils and neutrophils in whole blood.
Next Article:Is supine rest necessary before blood sampling for plasma metanephrines?
Topics:


Related Articles
Large-scale survey of cancer gene mutations.
Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: comparison of two high-resolution melting platforms.
Homogeneous amplification and mutation scanning of the p53 gene using fluorescent melting curves.
Utility of oligonucleotide array--based comparative genomic hybridization for detection of target gene deletions.
Rapid screening of multiple [beta]-globin gene mutations by real-time PCR on the lightcycler: application to carrier screening and prenatal diagnosis...
Rapid detection of [beta]-globin gene mutations and polymorphisms by temporal temperature gradient gel electrophoresis.
Denaturing HPLC procedure for factor IX gene scanning.
Novel technique for scanning of codon 634 of the RET protooncogene with fluorescence resonance energy transfer and real-time PCR in patients with...
Detection of mitochondrial DNA mutations by temporal temperature gradient gel electrophoresis.
Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA I by PCR-mediated site-directed mutagenesis.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters